Top-News
Biotechnologie USA

Arvinas Aktie

Aktie
WKN:  A2N6VP ISIN:  US04335A1051 US-Symbol:  ARVN
7,80 $
+0,59 $
+8,18%
6,8980 € 20:43:25 Uhr
Depot/Watchlist
Aktienanzahl *
68,77 Mio.
Marktkapitalisierung *
583,95 Mio. €
Streubesitz
-
Index-Zugehörigkeit
-
IR-Website
zur Website
*Stand: 11.03.2025

Arvinas News

28.01.25 - PR Newswire
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Arvinas, Inc. - ARVN
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Arvinas, Inc. - ARVN PR Newswire
21.01.25 - PR Newswire
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Arvinas, Inc. - ARVN
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Arvinas, Inc. - ARVN PR Newswire
08.01.25 - PR Newswire
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Arvinas, Inc. - ARVN
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Arvinas, Inc. - ARVN PR Newswire
02.01.25 - PR Newswire
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Arvinas, Inc. - ARVN
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Arvinas, Inc. - ARVN PR Newswire
27.12.24 - PR Newswire
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Arvinas, Inc. - ARVN
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Arvinas, Inc. - ARVN PR Newswire
03.12.24 - PR Newswire
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Arvinas, Inc. - ARVN
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Arvinas, Inc. - ARVN PR Newswire
02.05.23 - PR Newswire
Arvinas and Quantum Leap Healthcare Announce Clinical Study to Evaluate Vepdegestrant (ARV-471) in I-SPY-2 Endocrine Optimization Platform (EOP) Clinical Trial
Arvinas and Quantum Leap Healthcare Announce Clinical Study to Evaluate Vepdegestrant (ARV-471) in I-SPY-2 Endocrine Optimization Platform (EOP) Clinical Trial PR Newswire
09.05.22 - PR Newswire
GNS Healthcare and Arvinas Enter into Neuroscience Drug Discovery Collaboration
GNS Healthcare and Arvinas Enter into Neuroscience Drug Discovery Collaboration PR Newswire
09.08.21 - PR Newswire
Insilico Medicine Announces an AI-driven PROTAC R&D Collaboration with Arvinas
Insilico Medicine Announces an AI-driven PROTAC R&D Collaboration with Arvinas PR Newswire
09.08.21 - PR Newswire
Insilico Medicine Announces an AI-driven PROTAC R&D Collaboration with Arvinas
Insilico Medicine Announces an AI-driven PROTAC R&D Collaboration with Arvinas PR Newswire
23.07.21 - PR Newswire
Thinking about trading options or stock in Snap, Twitter, Trade Desk, Arvinas, or Intel Corp?
Thinking about trading options or stock in Snap, Twitter, Trade Desk, Arvinas, or Intel Corp? PR Newswire
14.12.20 - PR Newswire
Thinking about buying stock in Pfizer, Moderna, Arvinas, Veru, or Alexion Pharmaceuticals?
Thinking about buying stock in Pfizer, Moderna, Arvinas, Veru, or Alexion Pharmaceuticals? PR Newswire
06.08.20 - Börse Online
BB Biotech-Aktie: Biotechsektor im Blick der Börsianer - was das Papier kann
Vor allem wegen Covid-19 rückte der Biotechsektor zuletzt in den Fokus der Anleger. Davon profitiert auch die Beteiligungsgesellschaft BB Biotech. Von Tobias Schorr Um den ...
04.06.19 - PR Newswire
Bayer and Arvinas, Inc. to develop novel Proteolysis-Targeting Chimera candidates for humans and plants
Bayer and Arvinas, Inc. to develop novel Proteolysis-​Targeting Chimera candidates for humans and plants - Agreement worth more than $110 million includes the first-​ever research ...

Newssuche

Videos

newspaper
30.04.25 +22,47%
Technical Trading: Cotton Long Chance
Cotton Long Typ: Turbo Open End WKN: VP6N8D Hebel: 3,80 Laufzeit: OpenEnd Einstieg: Market ... Mehr »